SEARCH

SEARCH BY CITATION

References

  • Ashe K. H. and Zahs K. R. (2010) Probing the biology of Alzheimer’s disease in mice. Neuron 66, 631645.
  • Borchelt D. R., Thinakaran G. and Eckman C. B. et al. (1996) Familial Alzheimers disease-linked presenilin 1 variants elevate Abeta 1–42/1–40 ratio in vitro and in vivo. Neuron 17, 10051013.
  • Caldwell J. P., Bennett C. E. and McCracken T. M. et al. (2010) Iminoheterocycles as gamma-secretase modulators. Bioorg. Med. Chem. Lett. 20, 53805384.
  • Casas C., Sergeant N. and Itier J. M. et al. (2004) Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated A{beta}42 accumulation in a novel alzheimer transgenic model. Am. J. Pathol. 165, 12891300.
  • Cheng I. H., Palop J. J., Esposito L. A., Bien-Ly N., Yan F. and Mucke L. (2004) Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat. Med. 10, 11901192.
  • Chishti M. A., Yang D. S. and Janus C. et al. (2001) Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276, 2156221570.
  • Czirr E., Leuchtenberger S., Dorner-Ciossek C., Schneider A., Jucker M., Koo E. H., Pietrzik C. U., Baumann K. and Weggen S. (2007) Insensitivity to Abeta 42-lowering non-steroidal anti-inflammatory drugs (NSAIDs) and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations. J. Biol. Chem. 282, 2450424513.
  • Czirr E., Cottrell B. A. and Leuchtenberger S. et al. (2008) Independent generation of Abeta 42 and Abeta 38 peptide species by gamma-secretase. J. Biol. Chem. 283, 1704917054.
  • Davis J., Xu F., Deane R., Romanov G., Previti M. L., Zeigler K., Zlokovic B. V. and Van Nostrand W. E. (2004) Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J. Biol. Chem. 279, 2029620306.
  • De Strooper B., Vassar R. and Golde T. (2010) The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 6, 99107.
  • Dewachter I., Van Dorpe J. and Smeijers L. et al. (2000) Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin1. J. Neurosci. 20, 64526458.
  • Duyckaerts C., Potier M. C. and Delatour B. (2008) Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol. 115, 538.
  • Games D., Adams D. and Alessandrini R. et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373, 523527.
  • Hall A., Elliott R. L., Giblin G. M., Hussain I., Musgrave J., Naylor A., Sasse R. and Smith B. (2010) Piperidine-derived gamma-secretase modulators. Bioorg. Med. Chem. Lett. 20, 13061311.
  • Herzig M. C., Winkler D. T. and Burgermeister P. et al. (2004) Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci. 7, 954960.
  • Hieke M., Ness J. and Steri R. et al. (2010) Design, synthesis, and biological evaluation of a novel class of gamma-secretase modulators with PPARgamma activity. J. Med. Chem. 53, 46914700.
  • Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F. S. and Cole G. (1996) Correlative memory deficits, A beta elevation, and amyloid plaques in transgenic mice. Science 274, 99102.
  • Hussain I., Harrison D. C., Hawkins J. et al. (2010) TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to gamma-secretase modulation and amyloid-beta(42) lowering by GSM-10h. Neurodegener. Dis. in press.
  • Imbimbo B. P., Del Giudice E. and Colavito D. et al. (2007) 1-(3′, 4′-Dichloro-2-fluoro[1, 1′-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer’s disease without causing peripheral toxicity. J. Pharmacol. Exp. Ther. 323, 822830.
  • Imbimbo B. P., Hutter-Paier B., Villetti G., Facchinetti F., Cenacchi V., Volta R., Lanzillotta A., Pizzi M. and Windisch M. (2009) CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer’s disease. Br. J. Pharmacol. 156, 982993.
  • Jankowsky J. L., Fadale D. J. and Anderson J. et al. (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 13, 159170.
  • Knobloch M., Konietzko U., Krebs D. C. and Nitsch R. M. (2007) Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol. Aging 28, 12971306.
  • Kounnas M. Z., Danks A. M. and Cheng S. et al. (2010) Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer’s disease. Neuron 67, 769780.
  • Kukar T. L., Ladd T. B. and Bann M. A. et al. (2008) Substrate-targeting gamma-secretase modulators. Nature 453, 925929.
  • Leuchtenberger S., Beher D. and Weggen S. (2006) Selective modulation of Abeta42 production in Alzheimer’s disease: non-steroidal anti-inflammatory drugs (NSAIDs) and beyond. Curr. Pharm. Des. 12, 43374355.
  • McGowan E., Sanders S. and Iwatsubo T. et al. (1999) Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol. Dis. 6, 231244.
  • Moechars D., Dewachter I. and Lorent K. et al. (1999) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 64836492.
  • Mucke L., Masliah E. and Yu G. Q. et al. (2000) High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 40504058.
  • Nilsberth C., Westlind-Danielsson A. and Eckman C. B. et al. (2001) The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation. Nat. Neurosci. 4, 887893.
  • Oakley H., Cole S. L. and Logan S. et al. (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 1012910140.
  • Ohno M., Cole S. L., Yasvoina M., Zhao J., Citron M., Berry R., Disterhoft J. F. and Vassar R. (2006) BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol. Dis. 26, 134145.
  • Okochi M., Ishii K. and Usami M. et al. (1997) Proteolytic processing of presenilin-1 (PS-1) is not associated with Alzheimer’s disease with or without PS-1 mutations. FEBS Lett. 418, 162166.
  • Okochi M., Fukumori A., Jiang J., Itoh N., Kimura R., Steiner H., Haass C., Tagami S. and Takeda M. (2006) Secretion of the Notch-1 Abeta -like peptide during Notch signaling. J. Biol. Chem. 281, 78907898.
  • Page R. M., Baumann K. and Tomioka M. et al. (2008) Generation of Abeta 38 and Abeta 42 is independently and differentially affected by FAD-associated presenilin 1 mutations and gamma -secretase modulation. J. Biol. Chem. 283, 677683.
  • Page R. M., Gutsmiedl A., Fukumori A., Winkler E., Haass C. and Steiner H. (2010) APP mutants respond to {gamma}-secretase modulators. J. Biol. Chem. 285, 1779817810.
  • Portelius E., Van Broeck B., Andreasson U., Gustavsson M. K., Mercken M., Zetterberg H., Borghys H. and Blennow K. (2010) Acute effect on the abeta isoform pattern in CSF in response to gamma-secretase modulator and inhibitor treatment in dogs. J. Alzheimers Dis. 21, 10051012.
  • Radde R., Bolmont T. and Kaeser S. A. et al. (2006) Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 7, 940946.
  • Richter L., Munter L. M. and Ness J. et al. (2010) Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proc. Natl Acad. Sci. USA 107, 1459714602.
  • Rivkin A., Ahearn S. P. and Chichetti S. M. et al. (2010a) Purine derivatives as potent gamma-secretase modulators. Bioorg. Med. Chem. Lett. 20, 22792282.
  • Rivkin A., Ahearn S. P. and Chichetti S. M. et al. (2010b) Piperazinyl pyrimidine derivatives as potent gamma-secretase modulators. Bioorg. Med. Chem. Lett. 20, 12691271.
  • Selkoe D. J. (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev. 81, 741766.
  • Siman R., Reaume A. G., Savage M. J., Trusko S., Lin Y. G., Scott R. W. and Flood D. G. (2000) Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability. J. Neurosci. 20, 87178726.
  • Stanton M. G., Hubbs J. and Sloman D. et al. (2010) Fluorinated piperidine acetic acids as gamma-secretase modulators. Bioorg. Med. Chem. Lett. 20, 755758.
  • Sturchler-Pierrat C., Abramowski D. and Duke M. et al. (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl Acad. Sci. USA 94, 1328713292.
  • Suzuki N., Cheung T. T., Cai X. D., Odaka A., Otvos L. J., Eckman C., Golde T. E. and Younkin S. G. (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264, 13361340.
  • Weggen S., Eriksen J. L. and Das P. et al. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212216.
  • Weggen S., Eriksen J. L., Sagi S. A., Pietrzik C. U., Golde T. E. and Koo E. H. (2003a) Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J. Biol. Chem. 278, 3074830754.
  • Weggen S., Eriksen J. L., Sagi S. A., Pietrzik C. U., Ozols V., Fauq A., Golde T. E. and Koo E. H. (2003b) Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J. Biol. Chem. 278, 3183131837.
  • Wen P. H., Shao X. and Shao Z. et al. (2002) Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice. Neurobiol. Dis. 10, 819.
  • Zettl H., Weggen S., Schneider P. and Schneider G. (2010) Exploring the chemical space of gamma-secretase modulators. Trends Pharmacol. Sci. 31, 402410.